Drugs / PA-1-STK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00006216 | Aug 1997 → ? | malignant mesothelioma | Louisiana State University Health Sciences Center in New Orleans | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PA-1-STK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006216 ↗ |
| Modality | Vaccine | “This is a dose escalation study of PA-1-STK modified ovarian carcinoma vaccine” NCT00006216 ↗ |
| Route | Other | “Patients receive PA-1-STK modified ovarian carcinoma vaccine intrapleurally on day 1” NCT00006216 ↗ |